Who
Garo H. Armen
Exec. Chair & Principal Off
Company insider
Files Form 4 as: Exec. Chair & Principal Off, Performance Technologies; Chairman and CEO, Agenus; Director, MiNK Therapeutics; Director, Color Kinetics.
In numbers
- Trades disclosed
- 400
- Buys
- 32
- Sells
- 8
- Bought
- $9.9M
- Sold
- $5.3M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 22 Feb 2006
- Last trade
- 21 Aug 2026
- Last filed
- 24 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 Aug 2026filed 24 Aug 2026 | Performance TechnologiesBiotechnology | SEC FORM 4 Bought | $13K20,000 at $0.65 | filing |
| 21 Aug 2026filed 24 Aug 2026 | Performance TechnologiesBiotechnology | SEC FORM 4 Bought | $13K20,000 at $0.65 | filing |
| 20 Aug 2026filed 20 Aug 2026 | Performance TechnologiesBiotechnology | SEC FORM 4 Bought | $9,81116,634 at $0.5898 | filing |
| 20 Aug 2026filed 20 Aug 2026 | Performance TechnologiesBiotechnology | SEC FORM 4 Bought | $9,81416,634 at $0.59 | filing |
| 19 Aug 2026filed 20 Aug 2026 | Performance TechnologiesBiotechnology | SEC FORM 4 Bought | $9452,700 at $0.35 | filing |
| 19 Aug 2026filed 20 Aug 2026 | Performance TechnologiesBiotechnology | SEC FORM 4 Bought | $9452,700 at $0.35 | filing |
| 11 Aug 2026filed 12 Aug 2026 | Performance TechnologiesBiotechnology | SEC FORM 4 Bought | $7102,220 at $0.32 | filing |
| 11 Aug 2026filed 12 Aug 2026 | Performance TechnologiesBiotechnology | SEC FORM 4 Bought | $7102,220 at $0.32 | filing |
| 10 Aug 2026filed 12 Aug 2026 | AGEN Agenusoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,971,500 at $0.00 | filing |
| 10 Aug 2026filed 12 Aug 2026 | AGEN Agenusoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,971,500 at $0.00 | filing |
| 6 Aug 2026filed 10 Aug 2026 | Performance TechnologiesBiotechnology | SEC FORM 4 Bought | $151685 at $0.22 | filing |
| 6 Aug 2026filed 10 Aug 2026 | Performance TechnologiesBiotechnology | SEC FORM 4 Bought | $151685 at $0.22 | filing |
| 5 Aug 2026filed 6 Aug 2026 | Performance TechnologiesBiotechnology | SEC FORM 4 Bought | $1,2945,000 at $0.2588 | filing |
| 5 Aug 2026filed 6 Aug 2026 | Performance TechnologiesBiotechnology | SEC FORM 4 Bought | $1,3005,000 at $0.26 | filing |
| 30 Jul 2026filed 3 Aug 2026 | Performance TechnologiesBiotechnology | SEC FORM 4 Bought | $4,80626,291 at $0.1828 | filing |
| 30 Jul 2026filed 3 Aug 2026 | Performance TechnologiesBiotechnology | SEC FORM 4 Bought | $4,73226,291 at $0.18 | filing |
| 10 Jul 2026filed 14 Jul 2026 | AGEN AgenusBiotechnology | SEC FORM 4 Code A | $16K4,852 at $3.35 | filing |
| 10 Jul 2026filed 14 Jul 2026 | AGEN AgenusBiotechnology | SEC FORM 4 Code A | $16K4,852 at $3.35 | filing |
| 26 Jun 2026filed 30 Jun 2026 | AGEN AgenusBiotechnology | SEC FORM 4 Code A | $16K5,364 at $3.03 | filing |
| 26 Jun 2026filed 30 Jun 2026 | AGEN AgenusBiotechnology | SEC FORM 4 Code A | $16K5,364 at $3.03 | filing |
News
ImageneBio (NASDAQ:IMA) versus Agenus (NASDAQ:AGEN) Financial SurveyAGEN · dailypolitical.com · 11 Oct 2026
0 headlines in the last 90 days name Garo H. Armen; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.